BTC 
ETH 
BNB 
XRP 
SOL 
TRX Eli Lilly beats Q3 sales expectations, raises outlook on Mounjaro and Zepbound
Investor's Business Daily reported that Eli Lilly beat third-quarter sales expectations and raised its outlook, driven by Mounjaro and Zepbound. The post states that Eli Lilly stock jumped early Thursday following the report.
Why “Unverified”
- Reported by Investor's Business Daily alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
Market around the story
- LLY Still being measured. The price reaction is recorded once the market has traded for six hours after the first report.
What the sources claim
-
Eli Lilly's third-quarter sales exceeded expectations, according to the report. LLY
“Eli Lilly Blows Past Sales Expectations”
Investor's Business Daily -
Eli Lilly raised its outlook, per the report. LLY
“Hikes Outlook On Mounjaro, Zepbound Dominance”
Investor's Business Daily -
Eli Lilly stock jumped early Thursday after the report. LLY
“Eli Lilly stock jumped early Thursday on a solid third-quarter report”
Investor's Business Daily
Sources
More on LLY
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-10-29 13:00 UTC. Labels are computed from the sources, not by the model.